CAS 62253-63-8 Human Epidermal Growth Factor EGF Yeast Derived Non - Animal Component

CAS 62253-63-8 Human Epidermal Growth Factor EGF Yeast Derived Non - Animal Component

Description

EGF is a kind of growth factor used in research and skin cosmetics to promote cell growth. Its most important function is to promote cell growth. Non-Animal rEGF is derived from yeast by using the transgenic technology. It does not contain any animal-derived ingredients, so it is safer and more stable than blood-derived EGF.

Quick detail

1. CAS No.: 62253-63-8
2. Other Names: rhEGF, Recombinant epidermal growth factor, recombinant EGF, rEGF, EGF
3. EINECS No.: 263-468-7
4. Place of Origin: Wuhan, China (Mainland)
5. Brand Name: Oryzogen
6. Model Number: HYC020M01
7. Source: Yeast
8. Formulation: rhEGF is lyophilized with mannitol as the stabilizer

Advantages 

1. Healthgen Biotech quality control systerm has been certified by ISO 9001:2015 and ensure standardized process as well as qualified products.

2. Healthgen Biotech recombinant Human Epidermal Growth Factor(rhEGF) is free of animal origin, which effectively avoid any potential risk of animal bacteria, prions, virus and contagious protein disease.

3. Healthgen Biotech has a professional quality control department, in which 50% of them have master's degree or higher. There are 14 employees in the quality department, 9 of them are in QA and 5 are in QA. All of them have rich experience in analysis research or quality inspection. Half of them have graduated diploma. Every year there are more than 50 training courses, which cover GMP, SOP, specification, hygiene, QA, QC issues, etc.

We strictly control the quality of our products to ensure that all products into the market will be in line with quality standards.

Healthgen Biotech has a series of instruments, which are listed as below.

Supplemental Description 

The research results have been granted with 16 international patents, covering countries, such as United States, Japan, Europe, Canada and South Africa. Parts of the patents are showed as below:

A callus-specific promoter of rice and the use thereof

China patent no. 201110054109.X

Method for expressing small peptides using cereal non-storage proteins as fusion carrier in endosperm and the use thereof

US patent no. US20070289033

Japan patent no. JP2007-325594A

Europe patent no. EP1865064

Canada patent no. CA2587092

China patent no. 200610019285.9

A method for extracting recombinant human serum albumin from transgenic rice grain

South Africa patent no. 2013/04359

China patent no. 201010597544.2

A method for isolating and purifying recombinant human serum albumin from transgenic rice grain;

South Africa patent no. 2013/04358

China patent no. 201010606635.8

A method for isolating and purifying recombinant human serum albumin from transgenic rice grain

South Africa patent no. 2013/04358

US patent no. US9023990 B2

Production of recombinant human serum albumin with rice endosperm cells as biological reactor

China patent no. ZL 2005 1 0019084.4

Based on the innovative technology, Healthgen Biotech also published research papers.

Publications

1. He Y, et al. Large-scale production of functional human serum albumin from transgenic rice seeds. Proc Natl Acad Sci USA. 2011;108:19078-19083.

2. Na An, et al. Expression of a Functional Recombinant Human Basic fibroblast Growth Factor from Transgenic Rice Seeds. Int. J. Mol. Sci. 2013, 14, 3556-3567

3. Liping Z, et al. Expression and characterization of recombinant human alpha-antitrypsin in transgenic rice seed. Journal of Biotechnology. 2012; 164: 300-308.

4. Xie, T, et al. A biologically active rhIGF-1 fusion accumulated in transgenic rice seeds can reduce blood glucose in diabetic mice via oral delivery. Peptides 2008: 29: 1862-1870.

5. Zhen Chen, et al. Human serum albumin from recombinant DNA technology: challenges and strategies. Biochimica et Biophysica Acta. 2013; 1830: 5515-5525.

6. Zhen Chen, et al. Quantitation of the residual DNA from rice-derived recombinant human serum albumin. Analytical Biochemistry. 2014; 450: 4-10.

7. Jiquan Ou, et al. Transgenic rice endosperm as a bioreactor for molecular pharming. Plant Cell Rep (2014) 33:585–594

8. Kai fu, et al. Immunotoxicity assessment of rice-derived recombinant human serum albumin using human peripheral blood mononuclear cells. PLoS ONE 01/2014; 9(8): e104426.